Household contact management of drug-resistant tuberculosis: a global cost-effectiveness modelling analysis of expanded preventive treatment by age
A global cost-effectiveness modelling analysis suggests that expanding multidrug-resistant tuberculosis preventive treatment to household contacts up to age 45 without infection testing is cost-effective in most countries, though it requires substantial resources and carries a significant risk of adverse events.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Tuberculosis is an ancient disease that still claims millions of lives every year, but a particularly dangerous version of it is rising in prominence. This is drug-resistant tuberculosis, a form of the illness that does not respond to the standard medicines used for decades. When a person develops this resistant strain, it spreads to the people they live with, creating a silent crisis within families. The people closest to an infected individual face the highest risk of catching the disease themselves. For years, doctors have known that giving preventive medicine to these household contacts can stop the disease before it starts, but a major question remained: who exactly should get this medicine, and how far should we go? The rules have traditionally favored young children, who are most vulnerable, but as people age, the risk of developing the disease after exposure drops, while the risk of side effects from the medicine rises. This creates a difficult balancing act for health officials trying to protect entire populations without causing harm or wasting limited resources.
A new study set out to solve this puzzle by looking at the math behind the medicine. Researchers built a detailed computer model to simulate how tuberculosis spreads through families in nearly every country on Earth. They tested different strategies for managing household contacts of people with drug-resistant tuberculosis. The core idea was to see if expanding preventive treatment to older adults, beyond just children, would be worth the cost and the potential side effects. The team also investigated whether it was necessary to test every person for infection first, or if it made more sense to treat everyone exposed, regardless of a test result. By running thousands of simulations, they could predict how many cases of tuberculosis would be prevented, how many lives would be saved, and how much money and medical resources would be required for each approach.
The findings paint a clear picture of a strategy that works, but one that demands significant effort. The researchers discovered that expanding preventive treatment to include adults up to the age of 45 is a cost-effective move in the vast majority of countries. In fact, in 160 out of 189 nations modeled, this expansion saves money or provides excellent value for the health gained. In 46 of these countries, the strategy actually saves the health system money overall because preventing the disease is cheaper than treating it later. The study suggests that the most efficient way to do this is to treat everyone in the household who is exposed, without stopping to test them for infection first. Testing people before giving them medicine turned out to be less effective and more expensive, because it missed many people who would have benefited from the treatment.
However, the study also highlights a serious trade-off. While treating everyone up to age 45 prevents nearly 12,000 new cases of tuberculosis and saves almost 10,000 lives globally, it also leads to a large number of adverse events. These are unwanted side effects from the medication. The model predicts that this expanded approach would result in about 71,000 serious side effects worldwide, with more than half of them occurring in people aged 45 and older. This means that health programs would need to be prepared to manage these reactions carefully. The researchers found that if they restricted treatment only to those who tested positive for infection, they would prevent fewer cases and save fewer lives, while still causing a significant number of side effects. The data suggests that the "test first" approach is not the most efficient path forward.
The study does not claim that this is a perfect or easy solution, but rather a calculated one. The simulations show that while the benefits are substantial, the costs and the number of people who will experience side effects are also substantial. In many places, the cost of implementing this full strategy would be high, requiring resources that some health systems might struggle to find. Yet, for the countries with the highest rates of tuberculosis, the model indicates that expanding treatment to adults under 45 is a logical step that aligns with the goal of stopping the disease. The research provides a roadmap for decision-makers, showing that treating the whole family, rather than just the youngest members or only those with a positive test, offers the best chance to reduce the burden of drug-resistant tuberculosis, provided the health systems are ready to handle the accompanying side effects.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.